---
document_datetime: 2026-01-26 17:11:01
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/levetiracetam-actavis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: levetiracetam-actavis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0171626
conversion_datetime: 2026-01-29 11:54:22.057649
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Levetiracetam Actavis

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 22/01/2026                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308189                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of veterinary medicinal products intended to implement the outcome of a procedure concerning PSUR: implementation of wording agreed by the competent authority - Accepted C.I.3.z - to update section 4.6 of the SmPC and section 2 of the PL to implement the wording agreed by the CHMP following the outcome of the PSUR procedure EMEA/H/C/PSUSA/00001846/202411. In addition, the MAH took the opportunity to submit editorial updates in section 6 of the Package Leaflet (list of local   |            |     |                |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| Variation type II / EMA/VR/0000290375 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/01/2026 | N/A | not applicable |

<div style=\"page-break-after: always\"></div>

| B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.z Reduction in the testing frequency of an analysis, from routine testing to skip or periodic testing (microbial testing of finished product). - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.g Addition or replacement (excluding biological or immunological product) of a specification parameter with its corresponding test method as a result of a safety or quality issue - Accepted B.II.d.2 Change in test procedure for the   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                          | finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                               |            |     |             |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA_IN / EMA/VR/0000316977 | This was an application for a group of variations. B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.3 New certificate from a new manufacturer (replacement or addition) - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved                                                                           | 10/12/2025 | N/A |             |
| Variation type IB / EMA/VR/0000256234    | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted | 26/06/2025 |     | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                                       | Type IB C.I.2.a - Update of section 4.8 of the SmPC and section 4 of the PIL to include additional information on signs and symptoms of Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS) following assessment of the same change for the reference product Keppra (EMEA/H/C/WS2722). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to introduce minor changes to the PI (also including a statement that 'this medicine does not require any special storage conditions'), and to align with the latest QRD template.   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000262087 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                 | 06/06/2025 | N/A |
| Variation type IA / EMA/VR/0000245357 | This was an application for a group of variations. B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                 | 22/01/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|